Peak Concentrations and Postdose Targets

What Does “Peak” Mean in Monitoring?

A concentration collected after a dose is not automatically the peak concentration. It is a measurement at a particular time on the concentration–time curve. If absorption is continuing, the concentration may still be rising; if distribution is occurring, it may already be falling rapidly. Interpreting a result as a peak without considering these processes can lead to an incorrect conclusion about whether an individual meets a target.

The exposure metric and the sampling definition must therefore be linked. A drug-specific target might refer to the maximum concentration over a dosing interval, or to a concentration measured at a standardized time after a dose or infusion. These quantities can differ. The target must be interpreted using the definition and sampling conditions for which it was established, rather than by treating every postdose measurement as interchangeable.

Definition: The peak concentration is the maximum concentration on a specified concentration–time profile or dosing interval. A postdose concentration is a concentration measured at a stated time after administration. A peak target is a target defined for a peak concentration or for a protocol-specified postdose measurement; the target’s meaning depends on which of these the protocol intends.

For a smooth modeled profile, a peak occurs where the concentration stops rising and begins to fall. In real monitoring, samples are collected at discrete times and assays have measurement error. The highest observed sample is therefore not guaranteed to be the true maximum. It is an estimate of the maximum only when the sampling design and pharmacokinetic model support that interpretation.

Absorption Can Delay the Peak

For a single oral dose, a useful starting model assumes first-order absorption into one apparent distribution compartment and first-order elimination. It also assumes linear pharmacokinetics, constant clearance and volume, no absorption lag, and a dose given at time zero. Let $F$ be bioavailability, $D$ the dose, $V$ the apparent volume, $k_a$ the absorption rate constant, and $k_e$ the elimination rate constant. Under these assumptions, the concentration at time $t$ after the dose is

C(t)=\frac{F D k_a}{V(k_a-k_e)} \left(e^{-k_e t}-e^{-k_a t}\right), \qquad k_a\ne k_e.

The two exponential terms represent different processes: drug enters the systemic circulation through absorption while drug is removed through elimination. Early after dosing, absorption can dominate and the concentration rises. Later, absorption contributes less and elimination dominates, so the concentration falls. The peak is determined by the balance between these processes; it is not generally at the time of dosing or at an arbitrary convenient sampling time.

Result: For the single-dose oral model above, the time of maximum concentration is $$ t_{\max}=\frac{\ln(k_a/k_e)}{k_a-k_e}. $$ This expression is positive for positive, unequal $k_a$ and $k_e$. It gives the model-predicted time of the peak, not a universal sampling time for all drugs or formulations.

The result follows by differentiating the concentration profile. The positive constant multiplying the exponentials does not affect where the derivative is zero:

\frac{dC(t)}{dt} =\frac{F D k_a}{V(k_a-k_e)} \left(-k_e e^{-k_e t}+k_a e^{-k_a t}\right).

At a stationary point, $k_a e^{-k_a t}=k_e e^{-k_e t}$. Taking logarithms gives $\ln(k_a/k_e)=(k_a-k_e)t$, which yields the stated $t_{\max}$. The derivative is positive at $t=0$, since its bracket is $k_a-k_e$ and the prefactor has the same sign as $k_a-k_e$; at sufficiently late times it is negative. Thus this stationary point is the maximum. If $k_a=k_e=k$, the limiting profile is proportional to $t e^{-kt}$, whose maximum occurs at $t=1/k$.

Worked Example: An Early Sample Is Not the Oral Peak

Suppose a hypothetical patient receives a single oral dose with $F D/V=12.0$ mg/L, $k_a=1.20$ h$^{-1}$, and $k_e=0.150$ h$^{-1}$. Assume the model conditions stated above. Find the peak time and peak concentration, then compare them with a sample taken 1.00 hour after the dose.

First calculate the model-predicted time of the peak:

t_{\max}=\frac{\ln(1.20/0.150)}{1.20-0.150} =\frac{\ln(8)}{1.05} =1.980\ \text{h}.

At that time, the concentration is

\begin{aligned} C_{\max} &=12.0\frac{1.20}{1.05} \left(e^{-0.150(1.980)}-e^{-1.20(1.980)}\right)\\ &\approx 12.0(1.1429)(0.7430-0.0929)\\ &\approx 8.92\ \text{mg/L}. \end{aligned}

The 1.00-hour sample is earlier than the predicted peak. Its modeled value is

\begin{aligned} C(1.00) &=12.0(1.1429)\left(e^{-0.150}-e^{-1.20}\right)\\ &\approx 13.714(0.8607-0.3012)\\ &\approx 7.67\ \text{mg/L}. \end{aligned}

For this hypothetical profile, the 1.00-hour result is a postdose concentration, not the peak: it is lower than the modeled maximum of 8.92 mg/L, which occurs at about 1.98 hours. If a target was specifically defined for the peak, comparing the 1.00-hour result directly with that target would misclassify the exposure unless a suitable model or validated sampling protocol justified the comparison.

Distribution Can Change What “Peak” Sampling Captures

After an intravenous dose or infusion, concentration may change quickly as drug distributes between blood and tissues. In a multicompartment profile, an early distribution phase can be followed by a slower terminal decline. For an illustrative post-infusion profile, a biexponential expression is

C(t)=A e^{-\alpha t}+B e^{-\beta t}, \qquad \alpha>\beta>0,

where $t$ is time since the end of infusion, $A$ and $B$ are concentration contributions, and $\alpha$ and $\beta$ are rate constants for faster and slower phases. This expression describes a falling post-infusion profile: it does not imply that a sample collected later is the maximum. During an infusion, concentration is increasing; at the end of infusion it may be high, then fall as distribution and elimination proceed. Some monitoring protocols deliberately define a postdistribution “peak” at a specified time after infusion, rather than using the concentration at the infusion’s end. That operational definition must not be confused with the mathematical maximum of the entire profile.

Worked Example: A Post-Infusion Value During Distribution

Consider a hypothetical post-infusion profile with $A=8.00$ mg/L, $B=2.00$ mg/L, $\alpha=2.00$ h$^{-1}$, and $\beta=0.200$ h$^{-1}$. Assume the biexponential model applies after the infusion ends. Find the concentration 1.00 hour after the infusion and explain what it represents.

Substitute the values into the profile:

\begin{aligned} C(1.00) &=8.00e^{-2.00(1.00)}+2.00e^{-0.200(1.00)}\\ &\approx 1.083+1.637\\ &=2.720\ \text{mg/L}. \end{aligned}

At the end of infusion, $t=0$, the model gives $C(0)=8.00+2.00=10.0$ mg/L. The 1-hour result of 2.720 mg/L is therefore a later post-infusion value on a declining profile, not the maximum of this post-infusion segment. It reflects both the fast distribution component, which has substantially declined by 1 hour, and the slower component. Whether 2.720 mg/L is an appropriate “peak” result depends on whether the target was defined for a standardized postdistribution sample; it cannot simply be substituted for an end-of-infusion concentration or another peak definition.

Sampling Time and Interpretation

A peak-target result is interpretable only when its timing and target definition match. Before drawing a conclusion, establish whether the target refers to a model-based maximum, a concentration at a specified time after an oral dose, or a specified time after an infusion. Also consider whether the assumptions behind the expected profile are plausible for the individual and regimen.

The following checks help identify when a peak interpretation may be unreliable:

Absorption may still be occurring. An early oral sample can be below the eventual peak. A delayed absorption process, food effect, formulation difference, or absorption lag can shift the peak later than expected.
Distribution may be incomplete. A very early post-infusion value can differ substantially from a later postdistribution value. The intended sampling convention matters.
The regimen may not match the model. A single-dose formula does not automatically describe repeated dosing with accumulation, altered dosing intervals, nonlinear kinetics, or a different route of administration.
Timing uncertainty can be important. When concentrations change quickly, a modest error in the time after dose or infusion can materially change the measured value.
A measured maximum depends on the sampling schedule. Sparse samples may miss the peak; a single postdose sample cannot establish the maximum without additional model or protocol support.

These checks are not a substitute for confirming the target definition and the dose history. They indicate when the result should be interpreted cautiously or evaluated with a method designed for the drug and sampling design. A trough target answers a different question about concentration near the end of a dosing interval. A peak target instead focuses on a maximum or a specified postdose point. Neither is inherently preferable: the relevant metric depends on the exposure–response evidence and the clinical purpose of monitoring.

Worked Example: Calculating a Peak Time and Checking a Target

For another hypothetical single oral dose, let $F D/V=10.0$ mg/L, $k_a=1.00$ h$^{-1}$, and $k_e=0.100$ h$^{-1}$. Assume first-order absorption and elimination, one compartment, and no absorption lag. A hypothetical target range is 7.50–8.00 mg/L for the modeled peak. Determine the peak time and peak concentration, and assess a sample collected at 2.00 hours.

The peak time is

t_{\max}=\frac{\ln(1.00/0.100)}{1.00-0.100} =\frac{\ln(10)}{0.900} =2.558\ \text{h}.

The concentration at the peak is calculated using the oral model:

\begin{aligned} C_{\max} &=10.0\frac{1.00}{0.900} \left(e^{-0.100(2.558)}-e^{-1.00(2.558)}\right)\\ &\approx 11.111(0.77426-0.07743)\\ &=11.111(0.69684)\\ &\approx 7.743\ \text{mg/L}. \end{aligned}

This modeled peak lies within the hypothetical 7.50–8.00 mg/L target range. A 2.00-hour sample is before the predicted maximum. Its modeled concentration is

\begin{aligned} C(2.00) &=11.111\left(e^{-0.200}-e^{-2.00}\right)\\ &\approx 11.111(0.8187-0.1353)\\ &\approx 7.593\ \text{mg/L}. \end{aligned}

The sample value also falls inside the numerical range, but that does not make it a measured peak. The peak is predicted at 2.558 hours. If the target applies only to the modeled maximum, the model-based peak is the relevant comparison; if the target protocol instead specifies a 2-hour postdose concentration, the 2-hour value is the relevant measurement. A shared numerical range does not make the two definitions equivalent.

Choosing and Using a Peak Target

A peak target is most useful when the clinical question concerns exposure near the maximum, and when the target has been established for a clearly specified peak definition. A fixed-time postdose target may be easier to implement operationally, but it is meaningful only if the dose, formulation, route, and sampling time are sufficiently standardized. A model-predicted maximum can accommodate a sample that is not collected exactly at the peak, but its reliability depends on the model, parameter estimates, and available data.

The main alternatives answer different questions. A trough concentration is measured near the end of the dosing interval and is not a proxy for the peak. A fixed-time postdose concentration is directly tied to a sampling time, not necessarily to a maximum. A model-based estimate of $C_{\max}$ attempts to infer the maximum from a concentration–time model. Exposure summaries such as AUC address overall exposure rather than a single point on the profile. The metric should be chosen for the monitoring objective; one should not convert among these measures by assumption.

A common mistake is to reason, “This was the highest sample collected after the dose, so it is the peak.” That is not necessarily true: an unsampled time may have had a higher concentration, especially when absorption is ongoing. The correction is to distinguish the observed sample from the peak, establish the target’s operational definition, and use the timing information and pharmacokinetic assumptions appropriate to that definition.

Key takeaway: A peak is a feature of a concentration–time profile; a postdose result is an observation at a particular time. Absorption can delay the maximum, while distribution can make early post-infusion values differ sharply from later postdistribution values. Interpret a result against the target definition and sampling conditions that generated it.

Check Your Understanding

Answer each question, then compare your reasoning with the concise solutions below.

Under the single-dose oral model, what does $t_{\max}$ describe, and why might a sample taken before $t_{\max}$ be below the peak?
A post-infusion sample is collected during a rapid distribution phase. Why might it not be interchangeable with a protocol-defined postdistribution peak?
For $k_a=0.800$ h$^{-1}$ and $k_e=0.200$ h$^{-1}$, calculate the model-predicted time of peak concentration.
Explain why the highest value among two postdose samples does not necessarily equal the true peak.

Solutions. (1) $t_{\max}$ is the time at which the modeled concentration reaches its maximum. Before that time, ongoing absorption can make the concentration rise further. (2) Distribution can rapidly change concentration after infusion, so a sample in that phase represents a different point on the profile from a later, standardized postdistribution sample. (3) $t_{\max}=\ln(0.800/0.200)/(0.800-0.200)=\ln(4)/0.600=2.310$ h. (4) The profile may reach a higher value between the two collection times or outside the sampled times; the maximum observed among sparse samples is not guaranteed to be the profile maximum.